Bristol-Myers Squibb Company announced that Daklinza(daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved by the U.S. FDA in combination with sofosbuvir (with or without ribavirin) in genotypes 1 and 3.  The expanded indication for Daklinza offers an additional treatment option for multiple subsets of patients who have genotype 1 or 3 chronic hepatitis C virus (HCV).  In July 2014, Japan became the first country in the world to approve the use of a daclatasvir-based regimen for the treatment of chronic hepatitis C. Since then, daclatasvir-based regimens have been approved in more than 50 countries across Europe, Central and South America, the Middle East and the Asia-Pacific region.

 

Source:

http://news.bms.com/press-release/hepc/us-fda-approves-expanded-use-bristol-myers-squibbs-daklinza-daclatasvir-additiona